chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt. developed a reaction to 1st dose COVID-19 vaccine.  Pt. has symptoms of tingling and bilater arms, no nausea.  Pt. has history of Ischemic stroke 9 yrs. ago.  No Rx of current medication.  No hospital care provided.  Pt verbalizes feeling better and recovered.  Pt. VS: 107/74, 80 P, 99% O2Sat,  Standing BP 117/73, 86 P, 97% O2Sat.
TASTE LESSENING ABOUT 3 WEEKS AFTER RECEIVING VACCINE  AND OVER THE LAST 3 WEEKS IT LOST COMPLETELY; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN expiry: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced taste lessening about 3 weeks after receiving vaccine and over the last 3 weeks it lost completely. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of taste lessening about 3 weeks after receiving vaccine and over the last 3 weeks it lost completely was not reported. This report was non-serious.
This spontaneous report was received from a physician referring to three patients of unknown age and gender. The medical history and concurrent condition of the three patients were not reported. On an unknown date, the three patients were vaccinated with ZOSTAVAX. Strength, dose, frequency, route of administration, lot number and expiration date were not provided. No concomitant therapies were reported. On an unknown date, the three patients got shingles (herpes zoster) after getting ZOSTAVAX. No Product Quality Complaint (PQC) was involved. The outcome of the event of shingles for the three patients was unknown at the time of the report. The causality of shingles (herpes zoster) with ZOSTAVAX was not provided. Additional information has been requested.
Inappropriate schedule of vaccine administered; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved.            Concomitant medication was not provided. Treatment information was not provided. Action taken with respect to mRNA-1273 was not applicable. It was reported that the patient was given both the doses of Moderna vaccine two weeks apart.
Left arm red, swollen, hot to touch from shoulder to elbow, and itched x 4 days. Ice applied, Benadryl, and Ibuprofen given.
Information has been received from a physician concerning an 18 year old female who on 16-FEB-2007 was vaccinated with a dose of Zostavax instead of Varivax. The physician was unable to determine if there was product confusion. The patient was asymptomatic. Unspecified medical attention was sought. There was no product quality complaint involved. Additional information has been requested.
This case involves Adult and unknown gender patient who reported that it hurts but it's a fun pain while receiving vaccine INFLUENZA VACCINE. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for prophylactic vaccination. On an unknown date the patient developed a non-serious event "it hurts but it's a fun pain" (vaccination site pain) (unknown latency) following the administration of INFLUENZA VACCINE. Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable. It was not reported if the patient received a corrective treatment for the event (it hurts but it's a fun pain). At time of reporting, the outcome was Unknown for the event it hurts but it's a fun pain.
NONE. IIV4 GIVEN. Later found the vaccine expiry date was 5.20.15 GSK FLUARIX lot # SJ9E9 .5 IM.
LIGHT HEADED; NAUSEOUS ABOUT 90 MIN AFTER SHOT; TIRED A BIT EARLIER THAN NORMAL; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced light headed, nauseous about 90 min after shot, and tired a bit earlier than normal. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from light headed, and nauseous about 90 min after shot, and the outcome of tired a bit earlier than normal was not reported. This report was non-serious.
No additional AEs were reported, no further information provided; The physician reported that a patient received improperly stored vaccine; This spontaneous report was received from a physician, referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant therapies were not provided.  07-OCT-2022, the patient was vaccinated with 1 improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # w017571 has been verified to be valid, expiration date reported and established as 29-NOV-2023; formulation, strength, dose and route were not provided) for prophylaxis (product storage error).   The storage temperature of the vaccine was 10.1 degrees Fahrenheit (F) for a time frame of 51 hours. There was no previous temperature excursion. No additional adverse event (AE) was reported, no further information provided.
Swollen Lymph node on right armpit on 1/18/2021 painful feels like a bruise, to present time. On 1/20/2021 itching on right arm where I got the vaccine. Morning of 1/21/2021 itching on right arm, swollen hot to the touch. Numbing feeling on arm and fingers.
No adverse event; We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 043H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Jul-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 01-Jul-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023).    No relevant concomitant medications were reported. On 27 Jun 2023 vial was thawed. No treatment medication reported.   This case was for the 27th patient out of 30 reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-732645 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 07-Jul-2023: Vaccine information reported and narrative updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-732645:Master case (Patient 1)
I felt like my vision was changing and it felt like my pupils were very tiny. I felt a strange pressure in the top of my head. Not a typical headache but a weird pressure. I started feeling like I was clenching my teeth and my jaw. That night my arms were very jerky. I wasn?t thinking right. And every day since I feel like I?m tense muscles I?m dizzy I?m just not mentally like I used to be.
Patient had swelling and redness approximately 3 to 4 inches in diameter surrounding the injection site.  Patient works in a doctor's office, and she was instructed to return to the pharmacy to see if follow-up care would be needed.  Patient came to pharmacy during the afternoon of October 6th, and was instructed to use a cold compress and take ibuprofen or acetaminophen for pain.  Patient was also instructed to seek medical care if the reaction continued for another 24 hours.  The patient opted to go to urgent care that evening.  Outcome of urgent care visit is unknown.
About 12 hours after the injection, severe myalgias began affecting the back, hands, and knees primarily. Associated symptoms included headache, intermittent nausea, loss of appetite, fever (up to 102F), rigors, and severe malaise. I began taking Advil 400mg Q6H in order to bring down the fever and help with the severe myalgia. The fever and other symptoms were severe for approximately 26 hours. After 26 hours, the fever subsided and myalgia only remained in the lower back. Throughout this course, there was also severe left deltoid soreness and pain. Approximately 30 hours after vaccine administration, a swollen erythematous rash appeared on the left arm. It continued to  enlarge and was warm to the touch. This rash started to migrate down the deltoid and over the bicep and was fully gone about 4-5 days after vaccine administration.
Woke up in the middle of the night with chills/sweats.  This resolved by morning but patient noticed a red rash below the injection site.
Legs burned the night I received the vaccine.   I have had SEVERE muscle plain in my right leg since the second dose.  It is difficult to sleep, walk or do anything.  The only thing that mildly helps is massage therapy.   It has been almost 5 weeks now with minimal relief.
Narrative:  Patient reported headache, joint and muscle pain, and rash to injection site after receiving the first dose of vaccine.
Patient received two vaccines on Saturday 9/18 in the same arm due to complications in the left arm. Patient called today, 9/22, to report that her right arm had broken out in a rash and her right hand was swollen and she was having trouble closing her hand.
pt recvd vax;10jul95 devel erythematous, varicelliform, maculopapular rash w/ blisters;dx of varicella versus varivax made;
On 8/22/2023, Mother called clinic due to concern for patient experiencing possible side effects from vaccination. Patient received vaccines on 8-17-2023 (first doses of MMR, Varicella, and hepatitis A). Mother reported that patient has been having runny nose, intermittent cough since patient got the vaccines. No fever. Mother said that the cough is getting worse and that "it's getting down to his chest with nasal dripping" and patient is unable to sleep at night. Mother also reported that she gave patient 3.76 mL of Tylenol orally (based on weight) every 4 hours because Mother thinks that patient is also teething. No complaints of localized injection reactions. RN advise mother of patient to bring patient to the nearest urgent care for further care and evaluation due to cough "getting worse". Mother unable to detect if child is wheezing or not during the call. Education imparted to Mother of patient, and she verbalized understanding and agreed to bring child to the nearest urgent care.
Weakness; Headaches; Low grade fever - Temp 100, normally ~97.6; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weakness), HEADACHE (Headaches) and PYREXIA (Low grade fever - Temp 100, normally ~97.6) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Weakness), HEADACHE (Headaches) and PYREXIA (Low grade fever - Temp 100, normally ~97.6). At the time of the report, ASTHENIA (Weakness), HEADACHE (Headaches) and PYREXIA (Low grade fever - Temp 100, normally ~97.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In February 2021, Body temperature: 100 (Inconclusive) 100.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
COVID 19; COVID 19; This is a spontaneous report received from a contactable reporter(s) (Nurse). The reporter is the patient.  A 56-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Depression" (unspecified if ongoing); "Anxiety" (unspecified if ongoing); "known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: ZOLOFT; WELLBUTRIN. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering", and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (12Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (13Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (14Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (15Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (16Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (17Jul2022) Positive, notes: Tested antigen positive daily 12Jul-17Jul; (18Jul2022) Negative, notes: Tested antigen Negative 18Jul, 19Jul, 20Jul; (19Jul2022) Negative, notes: Tested antigen Negative 18Jul, 19Jul, 20Jul; (20Jul2022) Negative, notes: Tested antigen Negative 18Jul, 19Jul, 20Jul; (21Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today); (22Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today); (23Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today); (24Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today); (26Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today); (27Jul2022) Positive, notes: Tested antigen positive daily 21Jul - 27Jul (today). Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on available information , there is reasonable possibility of causal association between the events Drug Ineffective and COVID 19  and the suspect drug BNT162b2 .
BRIEF OVERVIEW: Admission Date: 6/23/2023 Discharge Date: Jun 25, 2023 Discharge Disposition:  home or self care   DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Syncope, unspecified syncope type [R55] Pneumonia due to COVID-19 virus [U07.1, J12.82] COVID-19 [U07.1]   HOSPITAL COURSE: Patient is a 78-year-old male with a significant history of Parkinson's, hypertension, diabetes type 2, coronary artery disease and P 80 who presented with weakness, syncope and decreased appetite with recent fever.  He tested positive for COVID and was admitted for further treatment and evaluation.  Throughout hospital course, patient remained stable on room air, not requiring supplemental oxygen or steroids.  Due to age and concomitant comorbid issues, he was started on remdesivir.  Patient began to feel better, increasing his orally intake as well as tolerating working with therapy teams.  He was discharged after the 3rd dose of remdesivir and reporting near baseline clinical status.  No changes to his medications were made, and he was advised to closely follow up with his PCP.
weakness, SOB, diarrhea - pt went to ER. Admitted for sepsis
patient felt jaw pain, a strange taste (unable to describe), and numbness in her right arm  patient was monitered and symptoms resolved within 30 minutes of vaccine administration
Wife reported that shortly after administration, patient experienced approximately 12 hours of wheezing and shortness of breath.
Sore arm, big red bump, sore to touch, lasted one week. Headache started next day, lasted 2 days
constipation; bloating; gas; Headache; This is a spontaneous report from contactable consumers (one is reporting for himself and his wife). This consumer reported similar events for two patients. This is the first of two reports. A 73-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Batch/lot number: EL8982), intramuscular on 26Jan2021 10:20 at single dose on the left arm for COVID-19 immunization, reported as "to prevent covid". Vaccination facility type was medical center. Vaccine was not administered at military facility. There were no medical history and concomitant medications. No additional vaccines administered on same date of Pfizer suspect. The patient reported side effects of constipation, bloating and gas after the first dose of the Pfizer COVID-19  vaccine. No prior vaccinations within four weeks and no events prior vaccinations. This is the report for the caller himself. They looked at symptoms on the vaccine fact sheet and they did not have any of those symptoms. They received the first dose of the vaccine on 26Jan2021. The first couple of days on 27Jan2021, they had a little bit of a headache. The third day (29Jan2021), they started having constipation and bloating which was not normal for them. He has taken enough stuff which should have cleared it out. They were having a lot of gas and were very bloated. They are asking if anyone else has reported this since it is unusual for them. His wife comes on the line at times to provide details throughout the call. For treatment, patient reported that he took Tylenol with aspirin, took a sinus pill called Mucinex, to make sure it was not his sinuses. Patient took a lot of stuff for the constipation. The events did not require emergency room and physician office visit. When asked for height, the patient thinks he was shrinking. Outcome of the event headache was recovered on 29Jan2021 while for other events was not recovered (reported as ongoing). Relevant test was reported as none.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021149879 same reporter/drug/events, different patient
Allergic reaction to vaccine; Hives; This is a spontaneous report from a contactable consumer. An 8-month-old male patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), second dose (lot number: X90022, expiry date: 01Nov20120) at 5-month-old via an unspecified route of administration in right thigh on 26Feb2019 14:37 at a single dose, then third dose (lot number: AF5647, expiry date: 31May20121) intramuscular in left thigh on 18Jul2019 10:32 at 0.5 ml single at 10-month-old for immunization. Medical history included diagnosed allergies. The patient's concomitant medication were not reported. The patient previously received first dose of pneumococcal 13-val conj vac (dipht crm197 protein), diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (DTAP), and hib vaccine (HIB); all on 12Nov2018 at 2-month-old for immunization. On May2019, the patient had an allergic reaction after receiving pneumococcal 13-val conj vac (dipht crm197 protein). The patient added that the patient had 2 instances of hives and was sent to an allergist. In Aug2019, the allergist said he felt the reaction was caused by the pneumococcal 13-val conj vac (dipht crm197 protein). The 1st hives reaction was in May2019 and the 2nd instance was in Jul2019. She said he got the vaccine on 18Jul2019 and broke out in hives on the 19Jul2019. She said the office was beginning to look into the ingredients in the vaccines. He was treated with over-the-counter Benadryl and the parents were given an epinephrine auto-injector, as a precaution, that was not used. He was seen on 05Aug2019. She said he had blood work for allergy testing including the ImmunoCap, IgE with component reflex. On 06Jul2019, IgE peanut, IgE Ara H2, IgE Ara h6, allergy testing to Egg white and allergy testing to Dog dander was positive. The outcome of the event allergic reaction to vaccine was recovered while the outcome of was unknown.
Vaccine was not discarded after the 6 hours, patient was accidently given the vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was not discarded after the 6 hours, patient was accidently given the vaccine) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     Concomitant products included DULAGLUTIDE (TRULICITY), OXYBUTYNIN CHLORIDE, FEXOFENADINE HYDROCHLORIDE (ALLEGRA), FAMOTIDINE, METOPROLOL TARTRATE, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR), FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), ROPINIROLE, EZETIMIBE and METFORMIN HYDROCHLORIDE (METFORMIN ER) for an unknown indication.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was not discarded after the 6 hours, patient was accidently given the vaccine). On 07-Apr-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine was not discarded after the 6 hours, patient was accidently given the vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided.
Information has been received from a health professional concerning a 13 month old female with no known pre-existing allergies, birth defects, or medical conditions, who on 13-MAY-2003 received a first subcutaneous dose of varicella virus vaccine live (Oka/Merck) (lot# 643586/0802M). There was no reported illness at the time of vaccination and no adverse events following prior vaccination. On 05-JUN-2003 at 09:05, the patient's dad phoned the physician's office to report that blisters were cropping up on the patient's trunk, legs and arms. The blisters reportedly were breaking, and crusting. It was indicted that calamine lotion was applied to the "crusts", and Benadryl was administered for itching. There were no relevant diagnostic tests and laboratory values. On 18-JUN-2003, the patient recovered. A product quality complaint was not reported. At the time of this report, the patient was now a 5 year old 57lb. 44 3/4 in. female.